Healthcare - Biotechnology - NASDAQ - US
$ 0.1021
-18.3 %
$ 23.6 M
Market Cap
None
P/E
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.[ Read More ]
The intrinsic value of one GOVXW stock under the base case scenario is HIDDEN Compared to the current market price of 0.102 USD, GeoVax Labs, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart GOVXW
FINANCIALS
0
REVENUE
-26.7 M
OPERATING INCOME
-26 M
NET INCOME
-25.2 M
OPERATING CASH FLOW
-48.9 K
INVESTING CASH FLOW
4.06 M
FINANCING CASH FLOW
0
REVENUE
-5.85 M
OPERATING INCOME
-5.82 M
NET INCOME
-9.3 M
OPERATING CASH FLOW
-20.7 K
INVESTING CASH FLOW
16.3 M
FINANCING CASH FLOW
Balance Sheet Decomposition
GeoVax Labs, Inc.
| Current Assets | 7.89 M |
| Cash & Short-Term Investments | 6.45 M |
| Receivables | 0 |
| Other Current Assets | 1.43 M |
| Non-Current Assets | 1.4 M |
| Long-Term Investments | 0 |
| PP&E | 210 K |
| Other Non-Current Assets | 1.19 M |
| Current Liabilities | 3.52 M |
| Accounts Payable | 2.8 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 717 K |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
GeoVax Labs, Inc.
| Revenue | 0 |
| Cost Of Revenue | 20.7 M |
| Gross Profit | -20.7 M |
| Operating Expenses | 6.02 M |
| Operating Income | -26.7 M |
| Other Expenses | -776 K |
| Net Income | -26 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-450.55%
ROE
-279.72%
ROA
-464.02%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
GeoVax Labs, Inc.
| Net Income | -26 M |
| Depreciation & Amortization | 74.2 K |
| Capital Expenditures | -48.9 K |
| Stock-Based Compensation | 1.07 M |
| Change in Working Capital | -356 K |
| Others | 872 K |
| Free Cash Flow | -25.2 M |
Wall Street Analysts Price Targets
GeoVax Labs, Inc.
GOVXW has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
GeoVax Labs, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
2.5 K USD 1
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
10 months ago
Dec 22, 2023
|
Bought 2.5 K USD
|
McKee Kelly T. Jr.
Chief Medical Officer |
+ 6944
|
0.36 USD |
|
1 year ago
Sep 25, 2023
|
Bought 5.02 K USD
|
McKee Kelly T. Jr.
Chief Medical Officer |
+ 9653
|
0.52 USD |
|
1 year ago
Aug 25, 2023
|
Bought 20 K USD
|
DODD DAVID A
President, CEO |
+ 35087
|
0.57 USD |
|
1 year ago
Aug 18, 2023
|
Bought 5.18 K USD
|
Reynolds Mark
CFO |
+ 10000
|
0.5179 USD |
|
1 year ago
Apr 24, 2023
|
Bought 20.4 K USD
|
DODD DAVID A
President, CEO |
+ 32000
|
0.6389 USD |
|
1 year ago
Apr 20, 2023
|
Bought 5.04 K USD
|
Reynolds Mark
CFO |
+ 8000
|
0.63 USD |
|
4 years ago
Sep 29, 2020
|
Bought 301 K USD
|
Reynolds Mark
CFO |
+ 60184
|
5 USD |
|
4 years ago
Sep 29, 2020
|
Bought 301 K USD
|
Reynolds Mark
CFO |
+ 60184
|
5 USD |
|
4 years ago
Sep 29, 2020
|
Bought 409 K USD
|
DODD DAVID A
President, CEO |
+ 81870
|
5 USD |
|
4 years ago
Sep 29, 2020
|
Bought 409 K USD
|
DODD DAVID A
President, CEO |
+ 81870
|
5 USD |
|
4 years ago
Sep 29, 2020
|
Bought 270 K USD
|
MCNALLY ROBERT T
Director |
+ 53925
|
5 USD |
|
4 years ago
Sep 29, 2020
|
Bought 270 K USD
|
MCNALLY ROBERT T
Director |
+ 53925
|
5 USD |
|
4 years ago
Sep 29, 2020
|
Bought 105 K USD
|
SPENCER JOHN N JR
Director |
+ 21024
|
5 USD |
|
4 years ago
Sep 29, 2020
|
Bought 105 K USD
|
SPENCER JOHN N JR
Director |
+ 21024
|
5 USD |
|
4 years ago
Sep 29, 2020
|
Bought 59.9 K USD
|
Kollintzas Dean G
Director |
+ 11987
|
5 USD |
|
4 years ago
Sep 29, 2020
|
Bought 59.9 K USD
|
Kollintzas Dean G
Director |
+ 11987
|
5 USD |
|
4 years ago
Sep 29, 2020
|
Bought 83.1 K USD
|
CHASE RANDAL D
Director |
+ 16613
|
5 USD |
|
4 years ago
Sep 29, 2020
|
Bought 83.1 K USD
|
CHASE RANDAL D
Director |
+ 16613
|
5 USD |
|
9 years ago
May 05, 2015
|
Bought 37.5 USD
|
CHASE RANDAL D
Director |
+ 200
|
0.1875 USD |
|
9 years ago
May 05, 2015
|
Bought 1.86 K USD
|
CHASE RANDAL D
Director |
+ 9800
|
0.19 USD |
|
9 years ago
Apr 23, 2015
|
Bought 1.78 K USD
|
Reynolds Mark
CFO |
+ 10000
|
0.178 USD |
|
9 years ago
Apr 22, 2015
|
Bought 1.73 K USD
|
Reynolds Mark
CFO |
+ 10000
|
0.1735 USD |
|
9 years ago
Apr 22, 2015
|
Bought 1.7 K USD
|
Reynolds Mark
CFO |
+ 10000
|
0.17 USD |
|
9 years ago
Apr 20, 2015
|
Bought 3.02 K USD
|
SPENCER JOHN N JR
Director |
+ 18000
|
0.1675 USD |
|
9 years ago
Apr 20, 2015
|
Bought 5.1 K USD
|
CHASE RANDAL D
Director |
+ 30000
|
0.17 USD |
|
12 years ago
Jan 31, 2012
|
Bought 10 K USD
|
Reynolds Mark
CFO |
+ 15000
|
0.67 USD |
|
12 years ago
Jan 31, 2012
|
Bought 22.5 K USD
|
Reynolds Mark
CFO |
+ 22500
|
1 USD |
|
12 years ago
Jan 16, 2012
|
Bought 20.1 K USD
|
Antebi Steven S.
Director |
+ 30000
|
0.67 USD |
|
12 years ago
Dec 30, 2011
|
Bought 10 K USD
|
SPENCER JOHN N JR
Director |
+ 14925
|
0.67 USD |
|
12 years ago
Dec 30, 2011
|
Bought 22.4 K USD
|
SPENCER JOHN N JR
Director |
+ 22388
|
1 USD |
|
12 years ago
Dec 30, 2011
|
Bought 22.4 K USD
|
Kollintzas Dean G
Director |
+ 22388
|
1 USD |
|
12 years ago
Dec 30, 2011
|
Bought 10 K USD
|
Kollintzas Dean G
Director |
+ 14925
|
0.67 USD |
|
12 years ago
Dec 30, 2011
|
Bought 168 K USD
|
DODD DAVID A
Director |
+ 168000
|
1 USD |
|
12 years ago
Dec 30, 2011
|
Bought 75 K USD
|
DODD DAVID A
Director |
+ 112000
|
0.67 USD |
|
12 years ago
Dec 30, 2011
|
Bought 100 K USD
|
ROBINSON HARRIET L
Chief Scientific Officer |
+ 149254
|
0.67 USD |
|
12 years ago
Dec 30, 2011
|
Bought 224 K USD
|
ROBINSON HARRIET L
Chief Scientific Officer |
+ 223881
|
1 USD |
|
12 years ago
Dec 30, 2011
|
Bought 44.8 K USD
|
MCNALLY ROBERT T
President/CEO |
+ 44775
|
1 USD |
|
12 years ago
Dec 30, 2011
|
Bought 20 K USD
|
MCNALLY ROBERT T
President/CEO |
+ 29850
|
0.67 USD |
|
12 years ago
Dec 30, 2011
|
Bought 22.5 K USD
|
Reynolds Mark
CFO |
+ 22500
|
1 USD |
|
12 years ago
Dec 30, 2011
|
Bought 10 K USD
|
Reynolds Mark
CFO |
+ 15000
|
0.67 USD |
|
14 years ago
Jul 02, 2010
|
Bought 2.5 K USD
|
Reynolds Mark
Chief Financial Officer |
+ 1000
|
2.5 USD |
|
14 years ago
Jun 11, 2010
|
Bought 6.64 K USD
|
NEWMAN MARK J
VP, Research & Development |
+ 2000
|
3.32 USD |
|
14 years ago
Jun 11, 2010
|
Bought 3.25 K USD
|
NEWMAN MARK J
VP, Research & Development |
+ 1000
|
3.25 USD |
|
14 years ago
Jun 10, 2010
|
Bought 7.04 K USD
|
ROBINSON HARRIET L
Chief Scientific Officer |
+ 2100
|
3.35 USD |
|
14 years ago
Jun 10, 2010
|
Bought 9.9 K USD
|
ROBINSON HARRIET L
Chief Scientific Officer |
+ 3000
|
3.3 USD |
|
14 years ago
Jun 10, 2010
|
Bought 990 USD
|
MCNALLY ROBERT T
President & CEO |
+ 300
|
3.3 USD |
|
14 years ago
Jun 09, 2010
|
Bought 1.78 K USD
|
Reynolds Mark
Chief Financial Officer |
+ 530
|
3.35 USD |
|
14 years ago
Jun 09, 2010
|
Bought 1.9 K USD
|
Reynolds Mark
Chief Financial Officer |
+ 570
|
3.34 USD |
|
14 years ago
Jun 09, 2010
|
Bought 3.3 K USD
|
Reynolds Mark
Chief Financial Officer |
+ 1004
|
3.29 USD |
|
14 years ago
Jun 08, 2010
|
Bought 1.29 K USD
|
ROBINSON HARRIET L
Chief Scientific Officer |
+ 400
|
3.225 USD |
|
14 years ago
Jun 09, 2010
|
Bought 2.99 K USD
|
MCNALLY ROBERT T
President & CEO |
+ 900
|
3.32 USD |
|
14 years ago
Jun 09, 2010
|
Bought 330 USD
|
MCNALLY ROBERT T
President & CEO |
+ 100
|
3.3 USD |
|
14 years ago
Jun 09, 2010
|
Bought 3.29 K USD
|
HILDEBRAND DONALD G
Director |
+ 1000
|
3.29 USD |
|
14 years ago
Jun 08, 2010
|
Bought 12 K USD
|
DODD DAVID A
Director |
+ 3702
|
3.25 USD |
|
14 years ago
Jun 08, 2010
|
Bought 3.24 K USD
|
DODD DAVID A
Director |
+ 1000
|
3.24 USD |
|
14 years ago
Jun 08, 2010
|
Bought 3.25 K USD
|
MCNALLY ROBERT T
President & CEO |
+ 1000
|
3.25 USD |
|
14 years ago
Jun 04, 2010
|
Bought 9.9 K USD
|
ROBINSON HARRIET L
Chief Scientific Officer |
+ 3000
|
3.3 USD |
|
14 years ago
Jun 03, 2010
|
Bought 1.65 K USD
|
ROBINSON HARRIET L
Chief Scientific Officer |
+ 500
|
3.305 USD |
|
14 years ago
Jun 01, 2010
|
Bought 3.49 K USD
|
MCNALLY ROBERT T
President & CEO |
+ 1000
|
3.49 USD |
|
14 years ago
May 21, 2010
|
Bought 8.2 K USD
|
Tsolinas Peter M
Director |
+ 2000
|
4.1 USD |
|
14 years ago
May 20, 2010
|
Bought 2.87 K USD
|
Reynolds Mark
Chief Financial Officer |
+ 796
|
3.6 USD |
|
14 years ago
May 21, 2010
|
Bought 4.2 K USD
|
MCNALLY ROBERT T
President & CEO |
+ 1000
|
4.2 USD |
|
14 years ago
May 21, 2010
|
Bought 3.95 K USD
|
MCNALLY ROBERT T
President & CEO |
+ 1000
|
3.95 USD |
|
14 years ago
May 21, 2010
|
Bought 11.6 K USD
|
DODD DAVID A
Director |
+ 2900
|
4 USD |
|
14 years ago
May 21, 2010
|
Bought 21.5 K USD
|
DODD DAVID A
Director |
+ 5377
|
3.99 USD |
|
14 years ago
May 21, 2010
|
Bought 326 USD
|
DODD DAVID A
Director |
+ 88
|
3.7 USD |
|
14 years ago
May 20, 2010
|
Bought 33.6 K USD
|
SPENCER JOHN N JR
Director |
+ 10100
|
3.33 USD |
|
14 years ago
May 20, 2010
|
Bought 3.9 K USD
|
MCNALLY ROBERT T
President & CEO |
+ 1000
|
3.9 USD |
|
14 years ago
May 20, 2010
|
Bought 3.7 K USD
|
MCNALLY ROBERT T
President & CEO |
+ 1000
|
3.7 USD |
|
14 years ago
May 20, 2010
|
Bought 1.8 K USD
|
DODD DAVID A
Director |
+ 500
|
3.6 USD |
|
14 years ago
May 20, 2010
|
Bought 1.63 K USD
|
DODD DAVID A
Director |
+ 459
|
3.55 USD |
|
14 years ago
May 20, 2010
|
Bought 1.7 K USD
|
DODD DAVID A
Director |
+ 500
|
3.4 USD |
|
14 years ago
May 20, 2010
|
Bought 1.7 K USD
|
DODD DAVID A
Director |
+ 500
|
3.39 USD |
|
14 years ago
May 20, 2010
|
Bought 2.34 K USD
|
DODD DAVID A
Director |
+ 699
|
3.35 USD |
|
14 years ago
May 19, 2010
|
Bought 3.4 K USD
|
MCNALLY ROBERT T
President & CEO |
+ 1000
|
3.4 USD |
|
14 years ago
May 18, 2010
|
Bought 1.72 K USD
|
Reynolds Mark
Chief Financial Officer |
+ 500
|
3.45 USD |
|
14 years ago
May 18, 2010
|
Bought 3.25 K USD
|
Reynolds Mark
Chief Financial Officer |
+ 1000
|
3.25 USD |
|
14 years ago
Jan 27, 2010
|
Sell 7.13 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 50000
|
0.1426 USD |
|
14 years ago
Jan 25, 2010
|
Sell 5.05 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 35000
|
0.1444 USD |
|
14 years ago
Jan 26, 2010
|
Sell 5.75 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 40000
|
0.1438 USD |
|
14 years ago
Jan 21, 2010
|
Sell 3.65 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 25000
|
0.146 USD |
|
14 years ago
Jan 19, 2010
|
Sell 3.62 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 25000
|
0.145 USD |
|
14 years ago
Jan 20, 2010
|
Sell 3.65 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 25000
|
0.146 USD |
|
14 years ago
Jan 13, 2010
|
Sell 1.45 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 10000
|
0.145 USD |
|
14 years ago
Jan 14, 2010
|
Sell 7.56 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 52500
|
0.144 USD |
|
14 years ago
Jan 12, 2010
|
Sell 5.28 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 35000
|
0.151 USD |
|
14 years ago
Jan 08, 2010
|
Sell 19.6 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 135000
|
0.1449 USD |
|
14 years ago
Jan 11, 2010
|
Sell 7.6 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 50000
|
0.152 USD |
|
14 years ago
Jan 06, 2010
|
Sell 10.4 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 65000
|
0.1602 USD |
|
14 years ago
Jan 07, 2010
|
Sell 6.8 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 45000
|
0.1511 USD |
|
14 years ago
Jan 04, 2010
|
Sell 12 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 75000
|
0.16 USD |
|
14 years ago
Jan 05, 2010
|
Sell 5.21 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 32500
|
0.1603 USD |
|
14 years ago
Dec 21, 2009
|
Sell 14 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 100000
|
0.14 USD |
|
14 years ago
Dec 22, 2009
|
Sell 8.36 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 60000
|
0.1393 USD |
|
14 years ago
Dec 28, 2009
|
Sell 6.98 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 50000
|
0.1397 USD |
|
14 years ago
Dec 29, 2009
|
Sell 24.9 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 180000
|
0.1386 USD |
|
14 years ago
Dec 30, 2009
|
Sell 15.3 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 110000
|
0.1394 USD |
|
15 years ago
Sep 25, 2009
|
Sell 205 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 880000
|
0.233 USD |
|
15 years ago
Sep 28, 2009
|
Sell 42.7 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 220000
|
0.1941 USD |
|
15 years ago
Sep 29, 2009
|
Sell 64.5 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 360000
|
0.1793 USD |
|
15 years ago
Sep 30, 2009
|
Sell 30.2 K USD
|
EMORY UNIVERSITY
10 percent owner |
- 175000
|
0.1726 USD |
|
15 years ago
Aug 24, 2009
|
Bought 6.76 K USD
|
SPENCER JOHN N JR
Director |
+ 50000
|
0.1353 USD |
|
15 years ago
Jun 30, 2009
|
Sell 7.73 K USD
|
ROBINSON HARRIET L
SVP, Research & Development |
- 42000
|
0.1841 USD |
|
15 years ago
Jul 01, 2009
|
Sell 2.8 K USD
|
ROBINSON HARRIET L
SVP, Research & Development |
- 15000
|
0.1867 USD |
|
15 years ago
Jun 26, 2009
|
Sell 29.7 K USD
|
ROBINSON HARRIET L
SVP, Research & Development |
- 161000
|
0.1845 USD |
|
15 years ago
Jun 29, 2009
|
Sell 8.31 K USD
|
ROBINSON HARRIET L
SVP, Research & Development |
- 45000
|
0.1847 USD |
|
15 years ago
Jun 24, 2009
|
Sell 42.7 K USD
|
ROBINSON HARRIET L
SVP, Research & Development |
- 202000
|
0.2115 USD |
|
15 years ago
Jun 25, 2009
|
Sell 24.6 K USD
|
ROBINSON HARRIET L
SVP, Research & Development |
- 125000
|
0.1968 USD |
|
15 years ago
Jun 22, 2009
|
Sell 15.8 K USD
|
ROBINSON HARRIET L
SVP, Resarch & Development |
- 60200
|
0.2625 USD |
|
15 years ago
Jun 23, 2009
|
Sell 12.3 K USD
|
ROBINSON HARRIET L
SVP, Resarch & Development |
- 49100
|
0.25 USD |
|
16 years ago
Apr 03, 2008
|
Bought 9.74 K USD
|
SPENCER JOHN N JR
Director |
+ 75000
|
0.1299 USD |
|
16 years ago
Dec 06, 2007
|
Bought 5.04 K USD
|
Reynolds Mark
Chief Financial Officer |
+ 30000
|
0.168 USD |
|
16 years ago
Dec 04, 2007
|
Bought 9.9 K USD
|
SPENCER JOHN N JR
Director |
+ 55000
|
0.18 USD |
7. News
8. Profile Summary
GeoVax Labs, Inc. GOVXW
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 23.6 M
Dividend Yield
0.00%
Description
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Contact
1900 Lake Park Drive, Smyrna, 30080
https://www.geovax.com
IPO Date
None
Employees
17
Officers
Dr. Mark J. Newman Ph.D.
Chief Scientific Officer
Mr. Mark W. Reynolds CPA
Chief Financial Officer & Corporate Secretary
Mr. David Alan Dodd
Chairman, President & Chief Executive Officer
Dr. John W. Sharkey Ph.D.
Vice President of Business Development
Mr. John Niles
Head of Commercial Operations
Dr. Harriet Latham Robinson Ph.D.
Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board
Mr. Jeffrey Welch
Head of Process Development & Manufacturing Operations
Dr. Kelly T. McKee Jr., M.D., M.P.H.
Chief Medical Officer
Mr. Thomas O'Brien
Vice President of Quality Systems & Compliance